Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

BMC Cancer

Sarah L Larsen³  Christina W Yde³  Anne-Vibeke Laenkholm⁶  Birgitte B Rasmussen¹  Anne Katrine Duun-Henriksen²  Martin Bak⁵  Anne E Lykkesfeldt³  Tove Kirkegaard⁴ 

[1] Department of Pathology, Herlev Hospital, Herlev, Denmark

[2] Statistics, Bioinformatics and Registry, Danish Cancer Society Research Center, Copenhagen, Denmark

[3] Breast Cancer Group, Unit of Cell Death and Metabolism, Danish Cancer Society Research Center, Copenhagen, Denmark

[4] Present address: Department of Surgery, Køge Hospital, Køge, Denmark

[5] Department of Clinical Pathology, Odense University Hospital, Odense, Denmark

[6] Department of Pathology, Slagelse Hospital, Slagelse, Denmark

关键词: Aurora kinase B;    Barasertib;    Tamoxifen;    Fulvestrant;    Breast cancer;    Antiestrogen resistance;   

Others  :  1161216
DOI  :  10.1186/s12885-015-1210-4

 received in 2014-12-19, accepted in 2015-03-18,  发布年份 2015

【 摘 要 】

Background

Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast cancer cells to identify biomarkers and novel treatment targets.

Methods

Antiestrogen sensitive and resistant T47D breast cancer cell lines were used as model systems. Parental and fulvestrant resistant cell lines were subjected to a kinase inhibitor library. Kinase inhibitors preferentially targeting growth of fulvestrant resistant cells were identified and the growth inhibitory effect verified by dose–response cell growth experiments. Protein expression and phosphorylation were investigated by western blot analysis. Cell cycle phase distribution and cell death were analyzed by flow cytometry. To evaluate Aurora kinase B as a biomarker for endocrine resistance, immunohistochemistry was performed on archival primary tumor tissue from breast cancer patients who have received adjuvant endocrine treatment with tamoxifen.

Results

The selective Aurora kinase B inhibitor barasertib was identified to preferentially inhibit growth of fulvestrant resistant T47D breast cancer cell lines. Compared with parental cells, phosphorylation of Aurora kinase B was higher in the fulvestrant resistant T47D cells. Barasertib induced degradation of Aurora kinase B, caused mitotic errors, and induced apoptotic cell death as measured by accumulation of SubG1 cells and PARP cleavage in the fulvestrant resistant cells. Barasertib also exerted preferential growth inhibition of tamoxifen resistant T47D cell lines. Finally, high percentage of Aurora kinase B positive tumor cells was significantly associated with reduced disease-free and overall survival in 261 ER-positive breast cancer patients, who have received tamoxifen as first-line adjuvant endocrine treatment.

Conclusions

Our results indicate that Aurora kinase B is a driving factor for growth of antiestrogen resistant T47D breast cancer cell lines, and a biomarker for reduced benefit of tamoxifen treatment. Thus, inhibition of Aurora kinase B, e.g. with the highly selective kinase inhibitor barasertib, could be a candidate new treatment for breast cancer patients with acquired resistance to antiestrogens.

【 授权许可】

   
2015 Larsen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Osborne CK, Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-47.
• [2]EbctcgEbctcg: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 2005, 365:1687-717.
• [3]Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995, 345:29-30.
• [4]Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer 2000, 89:817-25.
• [5]Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al.: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-38.
• [6]Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al.: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87:746-50.
• [7]Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-43.
• [8]Lykkesfeldt AE, Madsen MW, Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994, 54:1587-95.
• [9]Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995, 61:529-34.
• [10]Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 1997, 57:585-9.
• [11]Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sorensen BS, Lykkesfeldt AE: T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett 2014, 344:90-100.
• [12]Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al.: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009, 114:263-75.
• [13]Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, et al.: Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat 2010, 121:601-13.
• [14]Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW: Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 2013, 139:71-80.
• [15]Pancholi S, Lykkesfeldt A, Hilmi C, Banerjee S, Leary A, Drury S, et al.: ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and p90RSK. EndocrRelat Cancer 2008, 15:985-1002.
• [16]Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K: Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 2003, 85:33-47.
• [17]McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al.: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001, 142:2776-88.
• [18]Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al.: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-33.
• [19]Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-82.
• [20]Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-92.
• [21]Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-72.
• [22]Carmena M, Wheelock M, Funabiki H, Earnshaw WC: The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol 2012, 13:789-803.
• [23]Monier K, Mouradian S, Sullivan KF: DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci 2007, 120:101-14.
• [24]Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y: Cell cycle-dependent regulation of the human aurora B promoter. Biochem Biophys Res Commun 2004, 316:930-6.
• [25]Carmena M, Earnshaw WC: The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003, 4:842-54.
• [26]Boss DS, Beijnen JH, Schellens JH: Clinical experience with aurora kinase inhibitors: a review. Oncologist 2009, 14:780-93.
• [27]Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR: Aurora kinases as anticancer drug targets. Clin Cancer Res 2008, 14:1639-48.
• [28]Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Laenkholm AV, Bak M, Lykkesfeldt AE, Yde CW: A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene 2014; doi: 10.1038/onc.2014.351.
• [29]Lundholt BK, Briand P, Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 2001, 67:199-214.
• [30]Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B: The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene 2008, 27:4986-97.
• [31]Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J: Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007, 6:1869-76.
• [32]Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al.: The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008, 47:506-24.
• [33]Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009, 11:R11. BioMed Central Full Text
• [34]Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, et al.: Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000, 102:279-91.
• [35]Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al.: Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer 2010, 9:42. BioMed Central Full Text
• [36]Goto H, Kiyono T, Tomono Y, Kawajiri A, Urano T, Furukawa K, et al.: Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat Cell Biol 2006, 8:180-7.
• [37]Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY, et al.: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer. Oncogene 2014, 33:4985-96.
• [38]Hole S, Pedersen AM, Lykkesfeldt AE, Yde CW: Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Res Treat 2015, 149:715-26.
• [39]Katayama H, Sen S: Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta 2010, 1799:829-39.
• [40]Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al.: Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002, 62:5168-77.
• [41]Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al.: The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008, 140:295-302.
• [42]Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al.: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007, 13:3682-8.
• [43]Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al.: AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009, 69:4150-8.
• [44]Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, et al.: Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2013, 31:370-80.
• [45]Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, et al.: Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011, 22:431-7.
• [46]Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, et al.: A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res 2011, 35:1384-9.
• [47]Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al.: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011, 118:6030-6.
• [48]Zheng FF, Wu RC, Smith CL, O’Malley BW: Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol Cell Biol 2005, 25:8273-84.
• [49]Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G: High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlen ther Onkol 2012, 188:248-54.